Gossamer Bio Inc
Research Gossamer Bio Inc (GOSS) on Bullrun: market cap USD 100.21M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGOSS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 100.21M
- Financial periodQ1 2026
- RevenueUSD 55.54M
- Net income-USD 46.66M
- Free cash flow-USD 38.72M
Valuation Snapshot
latest market cap is USD 100.21M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 48.47M | -USD 170.37M | -USD 171.35M | n/a | -0.75 | USD 37.73M | USD 202.91M | -USD 122.76M |
| FY2024 | USD 114.70M | -USD 56.53M | -USD 3.47M | n/a | -0.25 | USD 46.07M | USD 0 | USD 29.49M |
| FY2023 | USD 0 | -USD 179.82M | -USD 159.16M | n/a | -1.18 | USD 32.11M | USD 12.43M | USD 62.77M |
| FY2022 | USD 0 | -USD 229.38M | -USD 187.44M | n/a | -2.71 | USD 111.97M | USD 23.60M | USD 12.08M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 100.21M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 724.40M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 203.94M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 205.12M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 205.01M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 856.76M | n/a | n/a | n/a |
About Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Gossamer Bio Inc's market cap?
Gossamer Bio Inc's market capitalization is USD 100.21M.
What does Gossamer Bio Inc do?
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.